최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0897371 (2013-05-18) |
등록번호 | US-9271996 (2016-03-01) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 379 |
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified n
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
1. A method of producing a protein of interest in a cell comprising contacting the cell with a PLGA microsphere particle, said PLGA microsphere particle consisting essentially of PLGA and having no amine-containing polymers or amino acids, said PLGA microsphere particle comprising a modified mRNA gr
1. A method of producing a protein of interest in a cell comprising contacting the cell with a PLGA microsphere particle, said PLGA microsphere particle consisting essentially of PLGA and having no amine-containing polymers or amino acids, said PLGA microsphere particle comprising a modified mRNA greater than 30 nucleotides in length encoding said protein of interest, wherein said modified mRNA consists of a nucleoside modification which is N1-methylpseudouridine in place of uridines, wherein the PLGA microsphere particle has a percent encapsulation efficiency of at least 68.1%, a particle size of at least 40 um and an actual RNA loading of at least 0.31 weight percent. 2. The method of claim 1, wherein the PLGA microsphere comprising the modified mRNA releases less than 50% of the modified mRNA in a 48 hour time period. 3. The method of claim 1, wherein the PLGA microsphere comprising the modified mRNA is stable in serum. 4. The method of claim 3, wherein the stability is determined relative to unformulated modified mRNA in 90% serum. 5. The method of claim 1, wherein contacting said mammalian cells or tissues occurs via a route of administration selected from the group consisting of intravenous, intramuscular, intravitreal, intrathecal, intratumoral, pulmonary, and subcutaneous. 6. The method of claim 1, wherein the PLGA microsphere further comprises a second modified mRNA. 7. The method of claim 6, wherein the PLGA microsphere further comprises a third modified mRNA. 8. The method of claim 1, wherein the modified mRNA comprises at least one 5′ terminal cap selected from the group consisting of Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine. 9. The method of claim 8, wherein the 5′ terminal cap is Cap1.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.